Drug facts
MoleculeCitalopram (Celexa)
Generics already compete: 9 makers on the market. 26 A-rated products from 9 makers substitute at the counter.
Celexa was first approved by the FDA on 07/17/1998 under NDA 020822; the application holder is Abbvie Inc.
The latest NADAC for CITALOPRAM HBR 20 MG TABLET is $0.03 per unit (as of 10/28/2026).
Holder Abbvie IncApplication NDA 020822Approved 07/17/1998
01Patents and exclusivity
When competition can legally begin. A generic can launch once both exclusivity and the last listed patent expire, unless a court or settlement says otherwise.
- Latest patent
- No Celexa patent listed in the Orange Book Orange Book
02Competition
- Generics
- 9 generic makers Orange Book
- First generic approved
- 10/28/2004 Orange Book
Every listingEach listing and maker behind the generics count.
Price erosionHow NADAC moves as generics enter.
PrescribersWho prescribes it, from Medicare data.
Available in the full Citalopram profile.See what is included
03Supply and price
- FDA drug shortage
- ClearNot on the current shortage list FDA shortages
- NADAC
- $0.03 per unitCITALOPRAM HBR 20 MG TABLET, mid-priced of 3 strengths, as of 10/28/2026 CMS NADAC
- Latest recall
- 01/26/2022Class II, Citalopram, Cardinal Healthcare FDA enforcement
04Product
- Application holder
- Abbvie Inc Orange Book
- Application
- NDA 020822 Orange Book
- First approved
- 07/17/1998 Orange Book
- Dosage forms
- capsule; solution; tablet
- Routes
- oral
Sources: FDA Orange Book, FDA Purple Book, FDA drug shortages, FDA enforcement reports and CMS NADAC, read through QOPE. Not medical or legal advice.